Zohar Daphne 4

What Happened

• Daphne Zohar, CEO of Seaport Therapeutics, was granted two derivative equity awards on April 30, 2026: 271,813 shares and 1,486,786 shares (total = 1,758,599). Both awards were recorded at $0.00 on the Form 4, indicating they are non-cash grants (derivative securities such as options or RSUs), not open-market purchases or sales.

Key Details

• Transaction date: April 30, 2026; Form 4 filed May 4, 2026.
• Reported acquisition: 271,813 shares and 1,486,786 shares, $0.00 price shown (derivative awards).
• Total shares from these grants: 1,758,599.
• Vesting: Footnote states the shares underlying the option will vest in 48 equal monthly installments following April 30, 2026, subject to continued service.
• Shares owned after the transaction: not specified in the filing.
• Filing timeliness: the Form 4 reports the April 30 transaction and was filed May 4; the filing does not indicate a late-reporting code.

Context

• These are grant/award entries (not purchases or sales). They typically represent stock options or restricted-equity awards that convert to shares only as they vest (and may require exercise if options). Such grants are common in executive compensation and do not reflect an immediate cash transaction or sale of shares.